Efficacy and Safety of Hydroxychloroquine and Azithromycin for Patients With Moderate to Severe COVID-19
Open, Multicentric, Non Randomized, Exploratory Clinical Trial to Assess the Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Acute Respiratory Syndrome (COVID-19) Caused by SARS-CoV-2 Virus
Sponsor: Azidus Brasil
Suspended
Azidus, the CRO hired for this study by Prevent Senior has lost the interest to conduct this study.
Listed as NCT04329572, this EARLY_PHASE1 trial focuses on COVID-19 and remains suspended. Sponsored by Azidus Brasil, it has been updated 7 times since 2020, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Suspended EARLY_PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Suspended EARLY_PHASE1
-
Dec 2022 — Jul 2024 [monthly]
Suspended EARLY_PHASE1
-
Dec 2021 — Dec 2022 [monthly]
Suspended EARLY_PHASE1
-
Jan 2021 — Dec 2021 [monthly]
Suspended EARLY_PHASE1
▶ Show 2 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Suspended EARLY_PHASE1
-
May 2020 — Nov 2020 [monthly]
Suspended EARLY_PHASE1
First recorded
Apr 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Azidus Brasil
For direct contact, visit the study record on ClinicalTrials.gov .